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Objectives. The purpose of this study was to determine the
efficacy of treatment with antiplatelet therapy and no anticoagu-
lation after high pressure assisted coronary stent implantation
performed without intravascular ultrasound (IVUS) guidance.
Background. Previous studies have shown that during IVUS-
guided Palmaz-Schatz coronary stenting, it is safe to withhold
anticoagulation when stent expansion has been optimized by high
pressure balloon dilation.
Methods. Patients that had successful coronary stenting with-
out IVUS guidance were treated with ticlopidine, 500 mg/day, and
aspirin, 325 mg/day, for 1 month and then received only aspirin,
325 mg/day, indefinitely. Patients were not treated with warfarin
(Coumadin) or heparin after successful stenting. Clinical and
angiographic events were assessed at 1 month.
Results. A total of 201 intracoronary stents were implanted in
127 patients with 137 lesions. The average number of stents per
lesion was 1.4 6 0.8, and the average number of stents per patient
was 1.6 6 1.1. Stent deployment was performed for elective
indications in 79% of procedures and for emergency indications in
21%. There were four stent thrombosis events for a per patient
event rate of 3.1% and a per lesion event rate of 2.9%.
Conclusions. After high pressure assisted stenting performed
without IVUS guidance, there was an acceptable incidence of 3.1%
of stent thrombosis with the combination of short-term ticlopidine
and aspirin therapy and no anticoagulation. Although the study
involved only 127 patients, the results support the relative safety
of stenting without IVUS guidance and with antiplatelet therapy
only in comparison to historical trials on stenting performed with
postprocedure anticoagulation.
(J Am Coll Cardiol 1977;29:21–7)
q1997 by the American College of Cardiology
Coronary stent implantation has been shown to reduce the
morbidity of acute or threatened vessel closure after coronary
angioplasty (1,2). The Belgian Netherlands Stent study
(BENESTENT) and Stent and Restenosis Study (STRESS)
randomized trials comparing stents to angioplasty in the
treatment of de novo coronary lesions demonstrated a signif-
icant reduction in the angiographic restenosis and late isch-
emia driven clinical events in the group treated with stents
(3,4). The BENESTENT trial also demonstrated a reduction in
major clinical events after coronary stent implantation in
comparison with coronary angioplasty (3). These contributed
to a marked increase in the use of intracoronary stents for the
treatment of symptomatic coronary artery disease. The utility
of stent implantation, however, continues to be limited by a
stringent postprocedure anticoagulation regimen that in-
creases vascular and bleeding complications without providing
sufficient protection against stent thrombosis (5–8).
A cause of stent thrombosis was proposed to be stent
underexpansion after a study of intravascular ultrasound
(IVUS) evaluation after stent deployment demonstrated that
80% of stents were underexpanded when the final result was
judged only with angiographic assessment (9,10). In a subse-
quent prospective study on IVUS-guided coronary stent im-
plantation in which stent expansion was optimized with the use
of high pressure balloon dilations, there was a 1.1% stent
thrombosis rate in 321 patients treated only with antiplatelet
therapy after a successful procedure (11,12).
The strategy of stent implantation with IVUS guidance and
elimination of postprocedure anticoagulation therapy also
resulted in a reduction in hospital stay (12). However, this
strategy adds to the expense and increases procedure time of
the stent implantation procedure. Thus, the purpose of the
present study was to evaluate the safety and efficacy of
treatment with combination ticlopidine and aspirin after a
successful stent implantation procedure guided by an angio-
graphic assessment only, without IVUS evaluation.
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Methods
From October 26, 1993 to October 25, 1994, 132 patients
underwent successful high pressure assisted intracoronary
stent implantation without IVUS guidance. A total of 127
patients (91 consecutive patients in Villa Bianca Hospital,
Bari, Italy, and 36 selected patients in Columbus Clinic, Milan,
Italy) had a successful coronary stent implantation and did not
receive anticoagulation after the stent procedure. The patients
from the Columbus Clinic were not a consecutive series of
patients because of the general policy of performing stent
implantation with IVUS guidance. These patients, however,
were not specifically or exclusively low risk patients. In this last
group of patients IVUS was not performed because of severe
proximal tortuosity in 12 patients (33%) or because of signif-
icant angulation (.458) at the lesion site after placement of a
stent with a coil design (Gianturco-Roubin, Wiktor, Cordis
stents) in 10 patients (28%).
In these patients the indication for stent implantation was
emergent (acute or threatened closure) in eight lesions (22%)
and nonemergent (chronic occlusions) in five lesions (14%).
These indications are comparable to the ones reported for the
entire group.
The entry criteria for the study were evidence of coronary
artery disease manifested by clinical symptoms or objective
evidence of myocardial ischemia or exercise testing, nuclear
scintigraphy or pharmacologic stress echocardiogram, and
angiographic evidence of single- or multiple-vessel disease with
a target lesion stenosis of .70% by visual assessment. Specific
exclusion criteria included 1) small vessels ,2.5 mm by visual
estimate; 2) angiographically diffuse distal disease that might
compromise outflow after stent insertion; 3) patients who were
taking Coumadin before the stent procedure and who required
anticoagulation with Coumadin for other medical reasons; and
4) suboptimal angiographic results due to residual dissection
or suboptimal expansion at the end of the stent procedure that
was thought to require continued short-term anticoagulation
therapy with Coumadin for 1 month. During the course of this
investigation five patients had successful stent implantation
without IVUS guidance and received Coumadin therapy after
the stent procedure for poor distal run off (n 5 2), compro-
mised side branch (n5 2) or residual dissection (n5 1). There
were no complications of stent thrombosis in these five pa-
tients.
Stent implantation procedure. Patients received aspirin,
325 mg, and calcium antagonists before the stent procedure.
All coronary tent implantation procedures were performed
from the standard femoral artery approach using an 8F or 9F
guiding catheter. A bolus of 10,000 U of heparin was admin-
istered after insertion of the femoral sheath. A repeat bolus of
5,000 U of heparin was given to maintain an activated clotting
time (ACT) .250 s or if the procedure was longer than 3 h.
Patients did not receive dextran or dipyridamole (Persantine)
before, during or after the stent procedure. After appropriate
baseline angiograms were obtained, lesion predilation was
performed. There were five different types of stents deployed
during this study: the Palmaz-Schatz stent (Johnson and John-
son Interventional Systems Co.), the Gianturco-Roubin stent
(Cook Cardiology), the Wiktor stent (Medtronic), the Micro
stent (Applied Vascular Engineering) and the Cordis stent
(Cordis Corp.). Palmaz-Schatz stents were hand-crimped on
balloons and delivered bare as previously described (12).
There was no balloon size selection protocol for the stent
optimization. Each operator selected an appropriate balloon
size based on his or her visual assessment of the angiographic
reference diameter. Typically, noncompliant balloons (NC
Shadow, SCIMED Life Systems, or High Energy, Mansfield)
were used for final high pressure dilations.
The indications for stent deployment were defined as
follows. Acute occlusion stent implantation was performed to
relieve ischemia associated with complete vessel closure
(100%) after angioplasty with Thrombolysis in Myocardial
Infarction (TIMI) flow grade 0 or 1. Threatened closure stent
implantation was performed when the angioplasty was compli-
cated by a longitudinal or spiral dissection associated with
.50% lumen encroachment (with or without compromised
flow) and symptomatic or electrocardiographic (ECG) evi-
dence of ischemia. Suboptimal result stent placement was
defined as insertion of a stent for a focal dissection or sig-
nificant vascular recoil after angioplasty that resulted in .50%
lumen narrowing not associated with ischemia. Restenosis stent
implantation was performed for lesions with a history of
restenosis after one or more previous angioplasty procedures.
Chronic occlusion stent insertion was performed after reopen-
ing a vessel that had been occluded for longer than 2 months.
Elective stenting was performed as the intention to stent de
novo lesions before the procedure. Emergency stent implanta-
tion was considered stent implantation performed for acute or
threatened closure and acute myocardial infarction.
Postprocedure medication protocol. A decision to treat
with only antiplatelet therapy at the completion of the stent
procedure required angiographic success, defined as the
achievement of ,20% residual stenosis and no evidence of
untreated residual dissection by visual assessment at the time
of the stent implantation procedure. After a successful stent
implantation procedure, no further heparin was infused. Fem-
oral sheaths were removed when the ACT dropped below
150 s. When a stent procedure was completed in the evening,
intravenous heparin was infused until the following morning
before being discontinued with subsequent sheath removal.
Ticlopidine was not administered before or during the stent
procedure but was initiated after a successful procedure.
Abbreviations and Acronyms
ACT 5 activated clotting time
BENESTENT 5 Belgian Netherlands Stent study
ECG 5 electrocardiographic, electrocardiogram
IVUS 5 intravascular ultrasound
STRESS 5 Stent Restenosis Study
TIMI 5 Thrombolysis in Myocardial Infarction
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Antiplatelet therapy with ticlopidine, 500 mg in two equal
doses per day, and aspirin, 325 mg/day, was initiated after a
successful stent procedure and continued for 1 month. After 1
month, ticlopidine was discontinued and patients were treated
with aspirin, 325 mg/day, indefinitely.
Quantitative angiographic measurements. Quantitative
coronary angiographic analysis was performed using digital
calipers by experienced angiographers not involved in the stent
procedure. Angiographic measurements were obtained during
diastole. The lesions were measured from an optically magni-
fied image in a single, matched “worst” view using digital
calipers (Brown and Sharp) using the guiding catheter as the
reference object for magnification calibration. Previous studies
have shown that digital calipers correlate closely with
computer-assisted methods with a low interobserver and in-
traobserver variability (13,14). Measurements of the reference
vessel diameters, minimal lumen diameter and diameter ste-
nosis were obtained on the baseline and final angiograms. The
average of the proximal and distal reference vessel diameters
was used as the index reference vessel diameter for percent
diameter stenosis calculations. When the lesions were total
occlusions or at an ostial location, only one reference vessel
measurement was possible on the baseline angiogram, and this
measurement site was used for the index reference diameters.
Lesion length was measured on the baseline angiogram as the
distance from the proximal to distal lesion shoulder. Lesions
were characterized according to the modified American Col-
lege of Cardiology/American Heart Association (ACC/AHA)
score (15). Thrombus was defined as a filling defect seen in
multiple projections surrounded by contrast agent in the
absence of calcification. TIMI flow grade was recorded at the
time of the initial procedure to characterize the indication for
stenting, as previously described (16).
Study end points and events. The study end points were
angiographic and clinical events that occurred within the first
month of a successful stent procedure. The short-term events
were carefully assessed through regular and uniform telephone
contact with all patients between 1 and 5 months after the stent
procedure. Any stent thrombosis occurring within the first
month of the stent procedure was considered an angiographic
event. Acute thrombotic events were defined as angiographically
documented occlusion with TIMI grade flow 0 at the stent site
occurring within 24 h of the stent procedure. Subacute throm-
botic events were angiographically documented occlusions with
TIMI flow grade 0 at the stent site occurring beyond 24 h of the
stent procedure. Major clinical events were considered death,
aortocoronary bypass surgery, myocardial infarction (Q wave
or non–Q wave) and emergency repeat intervention (bail-out
stenting or repeat angioplasty). Specific major event definitions
were as follows: death—any death irrespective of cause. A
diagnosis of myocardial infarction was made when new patho-
logic Q waves were documented ($0.14 s) on an ECG in
conjunction with elevation of creatine kinase to greater than
twice the upper limit of normal (Q wave myocardial infarction)
or if there was elevation of the cardiac enzymes to greater than
twice the upper limit of normal without the development of
new pathologic Q waves (non–Q wave myocardial infarction).
Emergency coronary artery bypass graft surgery involved imme-
diate transfer of the patient from the catheterization labora-
tory to the operating room. Nonemergent elective coronary
bypass surgery was performed more than 24 h after a stent
procedure had failed in the absence of ischemia or evolving
myocardial infarction. Emergency intervention was bail-out
stent implantation or emergency angioplasty performed for
ongoing acute ischemia or evolving myocardial infarction in
the setting of an angiographically documented stent thrombo-
sis event.
Statistics. Continuous variables were expressed as mean
value 6 SD. Angiographic measurements of baseline and
poststent implantation were compared using the paired two-
tailed t test. Comparisons between the stent thrombosis and
nonstent thrombosis groups were performed using the Fisher
exact probability test and the Mann-Whitney U test. Differ-
ences were considered statistically significant at p , 0.05.
Results
Clinical, angiographic and procedural characteristics. A
total of 127 patients with 137 stented lesions were treated only
with antiplatelet therapy after successful high pressure assisted
coronary stent implantation. Intravascular ultrasound evalua-
tion was not performed in any of the lesions. Baseline patient
and angiographic characteristics are shown in Tables 1 and 2.
Procedural characteristics of stent implantations are pre-
sented in Table 3. Elective stent placement was performed in
108 lesions (79%). Emergency stent deployment was done in
29 lesions (21%). A total of 201 stents were implanted with five
different types of stents being used. The average number of
stents per lesion was 1.4 6 0.8 (range 0.5 to 6.0). The average
number of stents per patient was 1.6 6 1.1 (range 0.5 to 6.0).
The short Palmaz-Schatz stent and 1- or 2-unit Micro Stents
(each unit is 4 mm) were considered half (0.5) stents for
calculating the mean number of stents per lesion or patient.
Table 1. Clinical Characteristics (n 5 127)
No. (%)
Lesions 137
Age (yr)* 58 6 10
Ejection fraction (%)* 536 11
Male 117 (82)
Previous myocardial infarction 40 (62)
Previous PTCA 27 (21)
Previous CABG 10 (8)
Multivessel disease 58 (45)
Unstable angina 56 (44)
Smoking 84 (66)
Hypercholesterolemia 66 (52)
Hypertension 54 (43)
Family history 46 (36)
Diabetes 21 (17)
*Mean value 6 SD. CABG 5 coronary artery bypass grafting; PTCA 5
percutaneous transluminal coronary angioplasty.
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More than one stent (multiple stents) were implanted in 34
lesions (25%) and 42 patients (33%).
Quantitative angiographic measurements and procedural
data are presented in Table 4. The baseline minimal lumen
diameter of 0.87 6 0.50 mm was significantly improved to a
final stent diameter of 2.94 6 0.89 mm. The percent diameter
stenosis was improved from 71 6 18% to 8 6 14%. The results
were achieved using a final balloon size of 3.36 0.4 mm (range
2.5 to 4.5). The maximal inflation pressure at final balloon
dilation was 17.4 6 2.4 atm (range 8 to 20). Pressure #10 atm
was used for the final balloon dilation in four lesions (3%). In
these lesions, final dilations were performed with an oversized
balloon to further improve the angiographic result, and low
pressure was used in an attempt to limit the risk of vessel
rupture. In all of these lesions, high pressure dilations with a
smaller, appropriately sized balloon by angiographic variables
preceded the final low pressure inflation. The final balloon/
artery ratio (proximal reference site) was 1.03 6 0.14. At the
time of postprocedure angiographic measurements, residual
dissection was noted at the stent site in six lesions (4.4%). The
dissection was proximal to the stent in two lesions (1.5%) and
distal to the stent in four lesions (2.9%).
Short-term angiographic and clinical events. The mean
hospital stay after stent implantation was 2.1 6 1.8 days.
Follow-up was obtained in all patients between 1 and 5 months
after the stent implantation procedure at a mean of 4.9 6 2.3
months. There were four stent thrombosis events, giving a per
lesion stent thrombosis event rate of 2.9% and a per patient
event rate of 3.1%. Acute stent thrombosis occurred in one
patient (0.8%) 3 h after the procedure. Subacute stent throm-
bosis occurred in three patients (2.4%) with one lesion each
(2.2%) at 3 days (n 5 1) and 5 days (n 5 2) after the stent
implantation procedure. The stent thrombosis events occurred
during the hospital stay in three patients (2.4%) and after the
hospital stay in one patient (0.8%). An emergency intervention
was performed in all four patients, with additional rescue stent
implantation being necessary in two of the patients (1.6%).
One of these patients underwent emergency bypass surgery
owing to extensive thrombus even after the intervention. One
patient developed Q wave myocardial infarction and three
patients had non–Q wave infarction.
No major clinical event occurred in the other patients
within the 1-month follow-up period. There was no vascular or
bleeding complications after the stent implantation procedure.
Leukopenia was noted in one patient (1%) due to ticlopidine
Table 2. Baseline Angiographic Characteristics (n 5 137)
No. (%)
Vessel distribution
LAD 75 (55)
RCA 32 (23)
LCx 19 (14)
SVG 9 (7)
LMCA 2 (1)
Lesion site
Ostial 7 (5)
Proximal 78 (58)
Mid 46 (33)
Distal 6 (4)
Lesion type*
A 20 (15)
B1 47 (34)
B2 39 (28)
C 31 (23)
Small vessels (,3.0 mm) 47 (34)
Bifurcations 24 (18)
Long lesions (.20 mm) 21 (15)
Chronic occlusions 16 (12)
Thrombus 11 (8)
Bend lesions (.45) 8 (6)
*Modified American Heart Association/American College of Cardiology
criteria. LCx 5 left circumflex coronary artery; LAD 5 left anterior descending
coronary artery; LMCA 5 left main coronary artery; RCA 5 right coronary
artery; SVG 5 saphenous vein graft.
Table 3. Stent Implantation Procedure Characteristics (n 5 137)
No. (%)
Emergency stent implantation 29 (21)
Threatened closure 23 (17)
Acute closure 5 (4)
Acute myocardial infarction 1 (1)
Nonemergent stent implantation 108 (79)
Elective 89 (65)
Suboptimal PTCA 7 (5)
Chronic occlusion 16 (12)
Total stents 201
Stent type and number
Palmaz-Schatz (15 mm) 126 (63)
Short Palmaz-Schatz (7 mm) 24 (12)
Gianturco-Roubin 29 (14)
Wiktor 16 (8)
Micro 4 (2)
Cordis 2 (1)
Number of stents/lesion
1 stent/lesion 103 (75)
2 stents/lesion 19 (14)
3 stents or more/lesion 15 (11)
Average number of stents/lesion* 1.46 0.8
Average number of stents/patient* 1.66 1.1
*Mean value 6 SD.
Table 4. Quantitative Angiographic Measurements (n 5137)
Baseline Final
Reference vessel (mm) 3.12 6 0.41 3.13 6 0.40
Minimal lumen diameter (mm) 0.87 6 0.50 2.94 6 0.89*
Diameter stenosis (%) 71 6 18 8 6 15*
Lesion length (mm) 12.22 6 7.72
Final balloon size (mm) 3.326 0.38
Balloon/artery ratio 1.036 0.14
Maximal inflation pressure (atm) 17.46 2.4
Residual dissection [no. (%)]† 6 (4.4%)
*p , 0.0001 (comparison between baseline and post-stent implantation).
†Dissection noted at the time of core laboratory angiographic measurements
were performed. Data are presented as mean value 6 SD, unless otherwise
indicated.
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within the first month of the stent procedure. This patient was
observed in the hospital for 5 days and leukopenia resolved
after discontinuation of ticlopidine.
Comparison between the stent thrombosis and no stent
thrombosis groups. The clinical and procedural factors in the
group with stent thrombosis (4 lesions) and the group with no
stent thrombosis (133 lesions) were analyzed (Table 5), al-
though statistical comparison between the two groups suffers
from the low number of overall patients and the low number of
stent thrombosis events. Stent thrombosis occurred more
frequently in lesions with occlusions at baseline angiography.
Dilation strategies also played a role in stent thrombosis. Stent
thrombosis occurred more frequently with a low final balloon/
artery (proximal reference) ratio and high residual stenosis
(.30%), which may be a reflection of the low final balloon/
artery ratio. The frequency distribution of the final percent
diameter stenosis, the balloon/artery ratio and final stent
minimal lumen diameter and the relation to stent thrombosis
are shown in Figure 1. There was no difference at the maximal
inflation pressure between two groups. None of the lesions
with stent thrombosis had angiographically evident calcifica-
tion or evidence of residual dissection at the time of the stent
implantation or at the time the final angiographic measure-
ments were performed.
Discussion
Previous IVUS-guided stent implantation studies demon-
strated the benefit of final high pressure balloon dilations to
appropriately and safely expand stents and emphasized the
clinical importance of achieving good stent expansion in pa-
tients treated only with antiplatelet agents and no postproce-
dure anticoagulation (10–12). The present study evaluated a
strategy of high pressure optimization without IVUS guidance
or postprocedure anticoagulation. In a mixed population of
127 patients who underwent both elective and emergency stent
implantation, there was a stent thrombosis event rate of 3.1%
per patient and there were no vascular or bleeding complica-
tions due to the absence of postprocedure anticoagulation.
Comparison with other studies. The stent thrombosis rate
in the present study was similar to the stent thrombosis rates of
3.5% for elective stent implantation in both the BENESTENT
and the STRESS trials, and slightly less than the stent throm-
bosis rate of 4.7% for both elective and emergency stent
implantation in the STRESS trial despite treatment without
Table 5. Factors Associated With Stent Thrombosis
Factors
No Stent
Thrombosis
(n 5 133)
Stent
Thrombosis
(n 5 4)
Unstable angina 58 (44) 2 (50)
Prior myocardial infarction 78 (59) 4 (100)
Emergency indication 28 (26) 0 (0)
Occlusion on baseline angiogram 18 (14) 2 (50)
Mean reference vessel (mm) 3.106 0.40 3.55 6 0.50
Baseline MLD (mm) 0.896 0.49 0.28 6 0.33*
Baseline diameter stenosis (%) 706 17 93 6 8*
Final stent MLD (mm) 2.966 0.89 2.26 6 0.29*
Final diameter stenosis (%) 76 15 34 6 3*
Lesion length (mm) 12.26 7.7 12.4 6 9.3
Inflation pressure (atm) 17.46 2.4 18.0 6 1.3
Balloon/artery ratio 1.046 0.15 0.90 6 0.06*
*p , 0.05. Data are presented as mean value 6 SD or number (%). MLD 5
Minimal lumen diameter.
Figure 1. A, Frequency distribution of final percent diameter stenosis.
B, Frequency distribution of balloon/artery (proximal reference) ratio.
C, Frequency distribution of final stent minimal lumen diameter.
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anticoagulation (3,4). The absence of vascular or bleeding
complications in the present study is in distinct contrast to the
7.1% and 13.5% vascular complication rates reported for these
multicenter trials. More recently, other investigators have
reported on the treatment with antiplatelet therapy and no
Coumadin after stent implantation performed with angio-
graphic evaluation only (17–21). Barragan et al. (17) reported
a stent thrombosis rate of 4.2% and an incidence of vascular
complications of 4.6% in 238 patients who were treated with
ticlopidine (started 3 days before stent implantation) and a
continuous heparin infusion for 24 h followed by low molecular
weight heparin after the stent implantation procedure. The
study was performed in an era when stent optimization with
high pressure balloon inflation was not a standard practice. A
strategy for treating only the ingress or the worst part of a
dissection may also have partially contributed to the relatively
high stent thrombosis rates. In contrast to the report of
Barragan et al. (17), more recent reports on stent implantation
performed without IVUS guidance and without anticoagula-
tion appear to be more favorable (18–21). In these reports,
poststent optimization was a standard practice, and patients
received a combination of ticlopidine and aspirin (18–20).
Morice, Cavalho and Jordan and their coauthors (18–20)
separately report a stent thrombosis rate of 0% to 1.5% with
a combination of ticlopidine (500 mg/day) and aspirin
(325 mg/day) therapy for at least 1 month with low molecular
weight heparin for 2 to 4 weeks. These studies were associated
with vascular or bleeding complications up to 4.8%. Use of
only ticlopidine and aspirin without low molecular weight
heparin after a successful stent procedure reduces vascular
complications without precipitating an increase in the inci-
dence of stent thrombosis.
As reported by Lablanche et al. (21), combination therapy
for 3 months with only ticlopidine (500 mg daily) and aspirin
(200 mg daily) in 98 patients after stent implantation resulted
in 0% stent thrombosis events, a 1.0% incidence of vascular
complications and a 1% rate of bleeding complications. Dif-
ferences in absolute stent thrombosis rates between the
present study and the more recent reports on treatment with
ticlopidine and aspirin after stent implantation may be the
result of differences in patient selection or other technical or
procedure-related factors.
Technical factors associated with stent thrombosis. The
importance of technical factors during the stent implantation
procedure in achieving both a high procedure success and low
postprocedure stent thrombosis rates, irrespective of the post-
stent implantation medical regimen, cannot be underesti-
mated. Although the use of large or angiographically oversized
balloons can also improve stent expansion, the consistent use
of this strategy is associated with increased procedural compli-
cations, including dissections and vessel rupture (10,12,22). A
reduction in procedural complications during stent optimiza-
tion was achieved when a strategy of using more appropriately
sized balloons (balloon/artery ratio 1.0 to 1.1) for final stent
optimization was used. In the present study, the importance of
technical factors during the stent implantation procedure is
revisited from a different perspective. Although the final stent
percent diameter stenosis of 8 6 14% is similar to or better
than most studies that employed only angiographic evaluation
during the stent implantation procedure, it is less than the
negative final percent diameter stenosis that was obtained
when stent implantation was performed with IVUS guidance,
which may have an impact on late angiographic or clinical
results (3,4,9,12). The analysis of the factors associated with
stent thrombosis illustrates that high pressure balloon dilations
are not a panacea, particularly when undersized balloons are
used for final poststent deployment optimization as demon-
strated by the frequency distribution histograms of the final
stent percent diameter stenosis, the final stent minimal lumen
diameter and the balloon/artery ratio (Fig. 1). The use of an
undersized balloon for final poststent deployment optimization
resulted in a high residual final stent percent diameter stenosis
and a significantly higher incidence of stent thrombosis. An
undersized balloon was used for final stent optimization in all
lesions with stent thrombosis. The association between a high
residual final stent diameter stenosis and subsequent stent
thrombosis is also consistent with previously published reports
on stent implantation (23,24).
Implications. It is important to put the results of the
present study on stent implantation without IVUS guidance or
subsequent anticoagulation therapy into a proper perspective
in the present era of intracoronary stent implantation. Even
with the reduction in vascular and bleeding complications, a
stent thrombosis rate of 3.1% per patient remains relatively
high, despite being comparable to the 3.5% incidence of stent
thrombosis in several large multicenter trials on stent implan-
tation (3,4). A decrease in the stent thrombosis rate will
require more vigorous attention to optimizing stent expansion
and covering flow-limiting dissections during the stent proce-
dure. On-line quantitative coronary angiography may offer an
improvement over visual angiographic estimation in the pre-
cise assessment of the final angiographic percent diameter
stenosis and may provide one means to further reduce stent
thrombosis. In an unselected cohort of patients, routine IVUS
after stent implantation may also help to reduce the stent
thrombosis rates to a more acceptable rate. Alternatively, the
selected use of IVUS may also benefit the resistant or complex
lesions, long lesions and multiple stents, cohorts that histori-
cally had a higher incidence of stent thrombosis. This strategy
may be of help without prohibitively increasing procedural
costs in all patients who undergo stent implantation. In addi-
tion to the use of good stent technique, preliminary reports
with heparin-coated stents appear to offer promise to reduce
stent thrombosis rates to below 1%, which should be consid-
ered the standard for an acceptable incidence of stent throm-
bosis (25).
Limitations. There are several limitations to the present
study. The study represents a relatively small series of patients
from two hospitals. The experience was a consecutive series at
one center of 91 patients, whereas at the other center it was not
a consecutive series because of the high percentage of patients
who underwent stent implantation with IVUS guidance. Al-
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though the standard period for assessing stent thrombosis is
the first month after stent implantation, this may result in an
underestimation of the incidence of stent thrombosis. This is
particularly possible since 12% of the lesions were chronic
occlusions, which may have a higher incidence of silent reoc-
clusions. The restenotic process and severe flow-limiting inti-
mal hyperplasia may have a role in precipitating late occlu-
sions. A large multicenter trial may be necessary to confirm the
results of this small study. An additional multicenter trial may
be needed to evaluate the role that IVUS may have after stent
implantation, particularly in patients at high risk of stent
thrombosis.
Conclusions. This observational study demonstrated the
feasibility of high pressure assisted stent implantation without
IVUS guidance using the combination treatment of ticlopidine
and aspirin after a successful procedure. This strategy of using
intracoronary stents should provide the benefit of decreased
restenosis while simultaneously reducing both the cost associ-
ated with routine IVUS guidance during stent insertion and
the complications related to anticoagulation after stent im-
plantation. Further reductions in stent thrombosis rates may be
derived from more careful angiographic assessment during the
stent implantation procedure, from the use of IVUS, particu-
larly in the higher risk subgroups, from better selection of
patients for stent implantation and possibly from heparin-
coated stents.
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